Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7595587 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TSHRALOX15L3MBTL1KEAP1 | |
| SCHEMBL779267 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TSHRALOX15TDP1HSD17B10 | |
| SCHEMBL10523999 | 0.84 | TSHR (0.35) | ALDH1A1TSHRALOX15KEAP1NFE2L2 | |
| SCHEMBL3990084 | 0.84 | TSHR (0.35) | ALDH1A1TSHRALOX15KEAP1NFE2L2 | |
| SCHEMBL17783667 | 0.83 | HSD17B10 (0.50) | ALDH1A1TSHRALOX15L3MBTL1TDP1 | |
| SCHEMBL6825661 | 0.80 | TSHR (0.35) | ALDH1A1TSHRALOX15L3MBTL1KEAP1 | |
| SCHEMBL30106390 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRALOX15TDP1HSD17B10 | |
| SCHEMBL27699936 | 0.78 | — | — | |
| SCHEMBL273328 | 0.78 | — | — | |
| SCHEMBL367441 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710180-A | Method for asymmetrically synthesizing sex pheromone of mealybugs of hibiscus syriacus | 中国农业大学 | 2023-02-24 | — | — | CN | claimed |
| EP-0239194-A2 | Methods for preparing hydroxy compounds and intermediates | SYMBICOM AB (SE) | 1987-09-30 | — | — | EP | claimed |
| CN-115710180-B | Method for asymmetrically synthesizing mealy bugle sex pheromone of hibiscus mani | 中国农业大学 | 2025-06-27 | — | — | CN | disclosed |
| EP-3709426-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ENERGY DEVICE USING SAME | MITSUBISHI CHEM CORP (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240199528-A1 | ISOBUTYRIC ACID ESTER COMPOUND HAVING ALKENOYLOXY GROUP AT ALPHA-POSITION, PERFUME COMPOSITION, AND USE AS PERFUME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-06-20 | — | — | US | disclosed |
| US-20240182932-A1 | SYNTHESIS OF ISOPRENOIDS AND DERIVATIVES | WILLIAM MARSH RICE UNIVERSITY (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240154170-A1 | NONAQUEOUS ELECTROLYTE, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY, AND ENERGY DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4349416-A1 | ISOBUTYRIC ACID ESTER COMPOUND HAVING ALKENOYLOXY GROUP AT a-POSITION, PERFUME COMPOSITION, AND USE AS PERFUME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117377743-A | Isobutyrate compound having enoyloxy group at alpha position, perfume composition and use as perfume | 三菱瓦斯化学株式会社 | 2024-01-09 | — | — | CN | disclosed |
| CN-113527079-B | Method for preparing 2-isopropenyl-5-methyl-4-hexenoic acid and derivative alcohol and carboxylic ester thereof | 信越化学工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| WO-1997048279-A1 | AGENTS WITH ANTIFUNGAL ACTIVITY AND METHODS OF USE THEREOF | UNIVERSITY OF ALBERTA (US) | 1997-12-24 | — | — | WO | disclosed |
| US-4871837-A | DEPROTECTING SILYL-PROTECTED CARBOHYDRATES, AMINO ACIDS, PEPTIDES; LEWIS ACID HYDROLYSIS | SYMBICOM AKTIEBOLAG (SE) | 1989-10-03 | — | — | US | disclosed |
| EP-0239194-A2 | Methods for preparing hydroxy compounds and intermediates | SYMBICOM AB (SE) | 1987-09-30 | — | — | EP | disclosed |
| EP-0007643-B1 | OXADIAZOLOTRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-15 | — | — | EP | disclosed |
| US-4336380-A | FOR USE AS HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-4276417-A | TREATMENT OF VASCULAR-CONDITION HYPERTENSION | HOFFMANN-LA ROCHE INC. (US) | 1981-06-30 | — | — | US | disclosed |
| EP-0007643-A1 | Oxadiazolotriazine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199528-A1 | ISOBUTYRIC ACID ESTER COMPOUND HAVING ALKENOYLOXY GROUP AT ALPHA-POSITION, PERFUME COMPOSITION, AND USE AS PERFUME | CYP1B1, CPT1A, FAAH2 | ALDH1A1 214/4885TSHR 4223/4885ALOX15 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.